伐伦克林的功效就是alpha4beta2烟碱乙酰胆碱受体部分激动剂,与安慰剂或缓释安非他酮戒烟:随机对照试验。

文章的细节

引用

复制到剪贴板

Jorenby DE,海斯特里,Rigotti NA·阿祖莱年代,Watsky EJ,威廉姆斯KE,账单CB,龚J, Reeves KR

伐伦克林的功效就是alpha4beta2烟碱乙酰胆碱受体部分激动剂,与安慰剂或缓释安非他酮戒烟:随机对照试验。

《美国医学协会杂志》上。2006年7月5日,296 (1):56 - 63。

PubMed ID

16820547 (在PubMed

]

文摘

背景:伐伦克林,部分激动剂alpha4beta2烟碱乙酰胆碱受体起作用,有可能帮助戒烟通过缓解尼古丁戒断症状和减少尼古丁的奖励属性。目的:确定伐伦克林的疗效和安全性戒烟与安慰剂比较或缓释安非他酮(安非他酮SR)。设计、设置和参与者:一项随机,双盲,安慰剂对照试验进行了2003年6月至2005年3月14日研究中心12周的治疗期和随访吸烟的状态52周。1413年成人吸烟者自愿参加这项研究,1027年注册;65%的随机参与者完成了这项研究。干预:伐伦克林滴定到1毫克每天两次(n = 344)或安非他酮SR滴定至150毫克每天两次(n = 342)或安慰剂(n = 341)为12周,加上每周简短戒烟咨询服务。主要结果测量:连续禁欲抽烟在过去4周的治疗(周9 - 12;主要终点),并通过随访期(周9-24和9-52)。结果:在过去4周的治疗(9 - 12周),43.9%的参与者在伐伦克林组不断有与之相比,安慰剂组17.6%(优势比[或],3.85;95%可信区间(CI), 2.69 - -5.50; P<.001) and 29.8% in the bupropion SR group (OR, 1.90; 95% CI, 1.38-2.62; P<.001). For weeks 9 through 24, 29.7% of participants in the varenicline group were continuously abstinent compared with 13.2% in the placebo group (OR, 2.83; 95% CI, 1.91-4.19; P<.001) and 20.2% in the bupropion group (OR, 1.69; 95% CI, 1.19-2.42; P = .003). For weeks 9 through 52, 23% of participants in the varenicline group were continuously abstinent compared with 10.3% in the placebo group (OR, 2.66; 95% CI, 1.72-4.11; P<.001) and 14.6% in the bupropion SR group (OR, 1.77; 95% CI, 1.19-2.63; P = .004). Treatment was discontinued due to adverse events by 10.5% of participants in the varenicline group, 12.6% in the bupropion SR group, and 7.3% in the placebo group. The most common adverse event with varenicline was nausea, which occurred in 101 participants (29.4%). CONCLUSIONS: Varenicline is an efficacious, safe, and well-tolerated smoking cessation pharmacotherapy. Varenicline's short-term and long-term efficacy exceeded that of both placebo and bupropion SR. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00143364.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

伐伦克林